Filter by: patients
Home > Community Treatment Reports and Side Effects > ALS Phase 2 Study KNS-760704 CL211 Treatment Report
What is ALS Phase 2 Study KNS-760704 CL211?

NCT00931944 is an open label, safety and tolerability, study evaluating the drug KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The drug KNS-760704 is now known as dexpramipexole. Other study ID include: KNS-760704-CL211. Read more...Click to read more below

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Participate in clinical trial 1 1 Efficacy_cant_tell

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 1
Moderate
 0
Mild
 0
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with ALS Phase 2 Study KNS-760704 CL211

Ringing in ears (tinnitus) 1
Loss of appetite 1

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 2 Study KNS-760704 CL211 (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 1   Side effects too severe: 100%
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped using ALS Phase 2 Study KNS-760704 CL211

Reported Duration See details about how long patients take this treatment ▼

Stopped Using ALS Phase 2 Study KNS-760704 CL211

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of ALS Phase 2 Study KNS-760704 CL211

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of ALS Phase 2 Study KNS-760704 CL211

Very
 0 0%
Somewhat
 1 100%
A little
 0 0%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of ALS Phase 2 Study KNS-760704 CL211

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on February 11, 2012.